Minerva Neurosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) filed the Company's New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia on April 27, 2023. The decision to file the NDA follows the Company's request for formal dispute resolution and appeal of FDA's October 2022 refuse to file letter. The issues cited in the refuse-to-file decision included those discussed at the type C meeting in April 2022.

In granting the appeal, the FDA deciding official agreed with the Company that the issues cited in the refuse-to-file decision should be considered during FDA's review of the NDA.